AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23595161 — intervention group
Group type: EXPERIMENTAL
Intervention: CALM-BP treatment
Number of subjects: 113
Study 23595161 — intervention group
Group type: COMPARATOR
Intervention: DASH+exercise control group
Number of subjects: 113
Study 21131550 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 120
Study 21131550 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 120
Study 21131550 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and Remifentanil
Number of subjects: 120
Study 18652319 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine comprehensive therapy and moxibustion at Zusanli (ST 36), Guanyuan (CV 4), Sanyinjiao (SP 6)
Number of subjects: 71
Study 18652319 — intervention group
Group type: COMPARATOR
Intervention: Routine comprehensive therapy (including hemodialysis and medication)
Number of subjects: 71
Study 16950175 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin treatment for 3 months
Number of subjects: 54
Study 16950175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 14505772 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed thank-you card, patient newsletters, and reminder (maximum group)
Number of subjects: 1558
Study 14505772 — intervention group
Group type: COMPARATOR
Intervention: No mailings (control group)
Number of subjects: 1558
Study 14505772 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey estimates (response rate 80%)
Number of subjects: 1558
Study 10766318 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with amoxicillin, clarithromycin, pantoprazole
Number of subjects: 172
Study 10766318 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with tinidazole, clarithromycin, ranitidine bismuth citrate
Number of subjects: 172
Study 10766318 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with tinidazole, clarithromycin, pantoprazole
Number of subjects: 172
Study 10766318 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy with tinidazole, tetracycline, bismuth, and pantoprazole
Number of subjects: 172
Study 10766318 — intervention group
Group type: COMPARATOR
Intervention: Triple therapies (all regimens)
Number of subjects: 172
Study 10766318 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Number of subjects: 172
Study 8823232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (50 mg/day)
Number of subjects: 18
Study 8823232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (100 mg/day)
Number of subjects: 18
Study 8823232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (150 mg/day)
Number of subjects: 18
Study 8823232 — intervention group
Group type: COMPARATOR
Intervention: Valproate (500 mg Depakote twice a day)
Number of subjects: 18
Study 1430709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1430709 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms fenoterol
Number of subjects: 6
Study 1430709 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms fenoterol
Number of subjects: 6
Study 1430709 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms fenoterol
Number of subjects: 6
Study 1430709 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms fenoterol
Number of subjects: 6
Study 3996846 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (3 to 22 micrograms/kg)
Number of subjects: 18
Study 3996846 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (7 micrograms/kg)
Number of subjects: 18
Study 30206423 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic therapy (RT) using the Armeo Power
Number of subjects: 34
Study 30206423 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy (OT)
Number of subjects: 34
Study 29513075 — intervention group
Group type: EXPERIMENTAL
Intervention: Health food messages with positive emotional valence, attractiveness, authoritative sender, longer arguments, and direct messages.
Number of subjects: 1496
Study 29513075 — intervention group
Group type: EXPERIMENTAL
Intervention: Health food messages with external evidence.
Number of subjects: 1496
Study 29513075 — intervention group
Group type: EXPERIMENTAL
Intervention: Health food messages with hashtags.
Number of subjects: 1496
Study 29513075 — intervention group
Group type: EXPERIMENTAL
Intervention: Health food messages containing only positive or negative emotions or direct messages without support information.
Number of subjects: 1496
Study 26758852 — intervention group
Group type: EXPERIMENTAL
Intervention: High activity group (Tegner≥5, n=115)
Number of subjects: 1000
Study 26758852 — intervention group
Group type: COMPARATOR
Intervention: Low activity group (Tegner≤4, n=885)
Number of subjects: 1000
Study 25353633 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed disc surgery
Number of subjects: 0
Study 25353633 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see (control)
Number of subjects: 0
Study 22409590 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg S-equol/day
Number of subjects: 102
Study 22409590 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg S-equol/day
Number of subjects: 102
Study 22409590 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg S-equol/day
Number of subjects: 102
Study 22409590 — intervention group
Group type: COMPARATOR
Intervention: Soy isoflavones
Number of subjects: 102
Study 19825901 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 0
Study 19825901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18312063 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted HIV risk reduction curriculum
Number of subjects: 380
Study 18312063 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 380
Study 16282844 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg for days 1-3; 100 mg for days 4-10)
Number of subjects: 12
Study 16282844 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 12
Study 16282844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12161769 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra®)
Number of subjects: 546
Study 12161769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study 10450540 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud packs combined with antidepressant treatment (trazodone)
Number of subjects: 0
Study 7759275 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation (ER) and an 8-week stress management (SM) program (ER + SM)
Number of subjects: 45
Study 7759275 — intervention group
Group type: COMPARATOR
Intervention: Exercise rehabilitation (ER) only
Number of subjects: 45
Study 2179067 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (400 mg bid)
Number of subjects: 115
Study 2179067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 396686 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methyl prednisolone administered immediately before bypass
Number of subjects: 31
Study 396686 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 31411516 — intervention group
Group type: EXPERIMENTAL
Intervention: Web platform access (including resources, forum and virtual interactions) for three months
Number of subjects: 28
Study 31411516 — intervention group
Group type: COMPARATOR
Intervention: Access to resources only (control group)
Number of subjects: 28
Study 31255240 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led dressing reconciliations in the intervention group.
Number of subjects: 39
Study 31255240 — intervention group
Group type: COMPARATOR
Intervention: Classic patient care in the control group.
Number of subjects: 39
Study 28435033 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 3011
Study 28435033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3011
Study 26519710 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% human albumin (5 mL/kg)
Number of subjects: 50
Study 26519710 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (5 mL/kg)
Number of subjects: 50
Study 23506005 — intervention group
Group type: EXPERIMENTAL
Intervention: New toothbrush with dentifrice
Number of subjects: 0
Study 23506005 — intervention group
Group type: COMPARATOR
Intervention: Old toothbrush with dentifrice
Number of subjects: 0
Study 23506005 — intervention group
Group type: EXPERIMENTAL
Intervention: New toothbrush without dentifrice
Number of subjects: 0
Study 23506005 — intervention group
Group type: EXPERIMENTAL
Intervention: Old toothbrush without dentifrice
Number of subjects: 0
Study 22034115 — intervention group
Group type: EXPERIMENTAL
Intervention: Varus contralateral knees
Number of subjects: 78
Study 22034115 — intervention group
Group type: COMPARATOR
Intervention: Neutral contralateral knees
Number of subjects: 78
Study 22034115 — intervention group
Group type: COMPARATOR
Intervention: Valgus contralateral knees
Number of subjects: 78
Study 22034115 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall contralateral knees followed longitudinally
Number of subjects: 78
Study 18478814 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% intracuff lidocaine
Number of subjects: 38
Study 18478814 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 38
Study 30311485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross 1×4
Number of subjects: 5
Study 30311485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross 1×7
Number of subjects: 5
Study 30311485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross 2×4
Number of subjects: 5
Study 30311485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross 1×6
Number of subjects: 5
Study 30311485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross 2×3
Number of subjects: 5
Study 30311485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross 2×5
Number of subjects: 5
Study 30311485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross 2×6
Number of subjects: 5
Study 30311485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross 2×7
Number of subjects: 5
Study 12920685 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluder endograft
Number of subjects: 100
Study 10699609 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (10-hertz square waves of 1-ms pulse duration, vaginal electrode for women, anal or surface electrode for men) for 15 minutes twice daily for 4 weeks
Number of subjects: 68
Study 10699609 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 68
Study 9112351 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 412
Study 9112351 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 412
Study 1547684 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 20
Study 1547684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3157577 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 43
Study 3157577 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol and hydralazine
Number of subjects: 43
Study 3157577 — intervention group
Group type: EXPERIMENTAL
Intervention: methyl dopa
Number of subjects: 43
Study 29872225 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 61
Study 29872225 — intervention group
Group type: COMPARATOR
Intervention: SitLess
Number of subjects: 61
Study 29872225 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit
Number of subjects: 61
Study 27404026 — intervention group
Group type: EXPERIMENTAL
Intervention: CE/BZA 0.45/20 mg
Number of subjects: 664
Study 27404026 — intervention group
Group type: EXPERIMENTAL
Intervention: CE/BZA 0.625/20 mg
Number of subjects: 664
Study 27404026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 664
Study 24560760 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (39Gy/13 fractions in 2.6 weeks)
Number of subjects: 71
Study 24560760 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (54Gy/30 fractions in 6 weeks)
Number of subjects: 71
Study 22188269 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related, height-based (ARHB)
Number of subjects: 0
Study 22188269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nose-ear-mid-umbilicus (NEMU)
Number of subjects: 0
Study 22188269 — intervention group
Group type: COMPARATOR
Intervention: Nose-ear-xiphoid (NEX)
Number of subjects: 0
Study 20537851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine administered every 30 minutes until the second hour, then every 4 hours for 48 hours
Number of subjects: 40
Study 20537851 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia with a mixture of 0.125% bupivacaine and 0.115% fentanyl continuously infused at 7 ml/h for 48 hours
Number of subjects: 40
Study 18504089 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 40
Study 18504089 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic Imagery
Number of subjects: 40
Study 18504089 — intervention group
Group type: COMPARATOR
Intervention: Control Condition
Number of subjects: 40
Study 15503293 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-thioguanine (TG) at a targeted dose of 50 mg/m²/day during maintenance therapy
Number of subjects: 12
Study 15503293 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-thioguanine (TG)
Number of subjects: 12
Study 12029227 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic retropubic urethropexy using non absorbable sutures
Number of subjects: 60
Study 12029227 — intervention group
Group type: COMPARATOR
Intervention: Prolene meshes fixed with tackers or staplers
Number of subjects: 60
Study 10581656 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitalograph bellows spirometer
Number of subjects: 6
Study 10581656 — intervention group
Group type: COMPARATOR
Intervention: MicroMedical turbine spirometer
Number of subjects: 6
Study 8934478 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 39
Study 8934478 — intervention group
Group type: COMPARATOR
Intervention: External fixation (with or without limited internal fixation)
Number of subjects: 39
Study 1877441 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 101
Study 1877441 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with metoprolol and nifedipine
Number of subjects: 101
Study 1877441 — intervention group
Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 101
Study 6193771 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 245
Study 6193771 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 245
Study 31994307 — intervention group
Group type: EXPERIMENTAL
Intervention: THD® Anopress manometry
Number of subjects: 60
Study 31994307 — intervention group
Group type: COMPARATOR
Intervention: High-resolution water-perfused manometry (WPM)
Number of subjects: 60
Study 31535388 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS at 110% RMT applied at the negative peak of the μ-rhythm
Number of subjects: 0
Study 31535388 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS at 110% RMT applied at the positive peak of the μ-rhythm
Number of subjects: 0
Study 31535388 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative peak-triggered 90% RMT TMS
Number of subjects: 0
Study 31535388 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 0
Study 28431480 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-ifosfamide chemotherapy
Number of subjects: 310
Study 28431480 — intervention group
Group type: COMPARATOR
Intervention: Single-agent doxorubicin
Number of subjects: 310
Study 28431480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (doxorubicin-ifosfamide)
Number of subjects: 310
Study 28431480 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-ifosfamide
Number of subjects: 310
Study 26547059 — intervention group
Group type: EXPERIMENTAL
Intervention: Likelihood text-messages in Study 1
Number of subjects: 797
Study 26547059 — intervention group
Group type: EXPERIMENTAL
Intervention: Likelihood text-messages in Study 2
Number of subjects: 797
Study 26547059 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity text-messages in Study 2
Number of subjects: 797
Study 26547059 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a picture with smokers' diseased lungs in Study 2
Number of subjects: 797
Study 25482242 — intervention group
Group type: EXPERIMENTAL
Intervention: NCC plus pill organizer
Number of subjects: 414
Study 25482242 — intervention group
Group type: EXPERIMENTAL
Intervention: NCC plus medication-dispensing machine
Number of subjects: 414
Study 25482242 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 414
Study 22514211 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (3 g/day for 4 weeks)
Number of subjects: 29
Study 22514211 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (3 g/day for 4 weeks)
Number of subjects: 29
Study 19460770 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (10 microg/kg/day) injection for 3 days after PCI in the AMI-G-CSF group.
Number of subjects: 76
Study 19460770 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (10 microg/kg/day) injection for 3 days after PCI in the OMI-G-CSF group.
Number of subjects: 76
Study 19460770 — intervention group
Group type: COMPARATOR
Intervention: Control group (no G-CSF treatment) in the AMI-control group.
Number of subjects: 76
Study 19460770 — intervention group
Group type: COMPARATOR
Intervention: Control group (no G-CSF treatment) in the OMI-control group.
Number of subjects: 76
Study 19460770 — intervention group
Group type: COMPARATOR
Intervention: Control group (no G-CSF treatment) in the healthy-control group.
Number of subjects: 76
Study 17526858 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate (360 mg twice daily)
Number of subjects: 7
Study 17526858 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (500 mg twice daily)
Number of subjects: 7
Study 17526858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 7
Study 15577621 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 therapy (9 x 10(6) IU/day for 4-5 days)
Number of subjects: 32
Study 11669254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Oss with Bio-Gide (M+)
Number of subjects: 29
Study 11669254 — intervention group
Group type: COMPARATOR
Intervention: Bio-Oss without Bio-Gide (M-)
Number of subjects: 29
Study 11669254 — intervention group
Group type: COMPARATOR
Intervention: Control implants in adjacent native bone
Number of subjects: 29
Study 9618617 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 injection of tetanus toxoid
Number of subjects: 41571
Study 9618617 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 injections of tetanus toxoid
Number of subjects: 41571
Study 9618617 — intervention group
Group type: COMPARATOR
Intervention: Unimmunized mothers
Number of subjects: 41571
Study 7999529 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation in ischaemic heart disease patients
Number of subjects: 712
Study 7999529 — intervention group
Group type: COMPARATOR
Intervention: High-risk controls (HR)
Number of subjects: 712
Study 7999529 — intervention group
Group type: COMPARATOR
Intervention: Low-risk controls (LR)
Number of subjects: 712
Study 3133712 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (75 mg)
Number of subjects: 75
Study 3133712 — intervention group
Group type: COMPARATOR
Intervention: Mianserin (60 mg)
Number of subjects: 75
Study 3133712 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (150 mg)
Number of subjects: 75
Study 30335073 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazepam (1 mg)
Number of subjects: 40
Study 30335073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28830517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus rituximab (IR)
Number of subjects: 754
Study 28830517 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine, cyclophosphamide and rituximab (FCR)
Number of subjects: 754
Study 25387888 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (10 mg once daily for 15 days)
Number of subjects: 26
Study 25387888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 23157654 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 72
Study 23157654 — intervention group
Group type: EXPERIMENTAL
Intervention: etanercept
Number of subjects: 72
Study 23157654 — intervention group
Group type: EXPERIMENTAL
Intervention: infliximab
Number of subjects: 72
Study 22014970 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration with 0.5% bupivacaine and i.m. 75 mg diclofenac (group BD)
Number of subjects: 96
Study 22014970 — intervention group
Group type: COMPARATOR
Intervention: Wound infiltration with saline and i.m. saline (group P)
Number of subjects: 96
Study 19164830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral quercetin (250 mg, 4x/day; 1,000 mg/day total)
Number of subjects: 63
Study 19164830 — intervention group
Group type: COMPARATOR
Intervention: Quercetin-free supplements
Number of subjects: 63
Study 19164830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral quercetin
Number of subjects: 63
Study 16862243 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (3 g/d)
Number of subjects: 0
Study 16862243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12506181 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil capsules
Number of subjects: 60
Study 12506181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11463999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified dietary counselling, ready-made liquid nutritional supplements free of charge, regular follow-ups
Number of subjects: 42
Study 11463999 — intervention group
Group type: COMPARATOR
Intervention: Simple dietary support (one session of individual dietary counselling, no supplements, no follow-ups)
Number of subjects: 42